Regulation of high-density lipoprotein metabolism

Circulation Research

Volumn 114, Issue 1, 2014, Pages 143-156

  Rye, Kerry Anne ^a   Barter, Philip J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

high density lipoprotein; lipoproteins

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; MESSENGER RNA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; PHOSPHOLIPID TRANSFER PROTEIN; PROCOLLAGEN C PROTEINASE; SECRETORY PHOSPHOLIPASE A2; SIGNAL PEPTIDASE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BIOGENESIS; CHOLESTEROL TRANSPORT; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HEART PROTECTION; HUMAN; INTRACELLULAR SIGNALING; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIPID COMPOSITION; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LOSS OF FUNCTION MUTATION; MACROPHAGE; METABOLIC REGULATION; NONHUMAN; PARTICLE SIZE; PLASMA FACTOR; PRIORITY JOURNAL; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; SURFACE CHARGE; TRANSCRIPTION REGULATION;

EID: 84892912948     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.300632     Document Type: Review

References (185)

1. Miller NE, Miller GJ. High-density lipoprotein and atherosclerosis. Lancet. 1975;1:1033
2. Hamilton RL, Williams MC, Fielding CJ, Havel RJ. Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver. J Clin Invest. 1976;58:667-680.
3. Hara H, Yokoyama S. Interaction of free apolipoproteins with macro-phages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem. 1991;266:3080-3086.
4. Lund-Katz S, Phillips MC. Packing of cholesterol molecules in human high-density lipoproteins. Biochemistry. 1984;23:1130-1138.
5. Stoffel W, Krüger E, Deutzmann R. Cell-free translation of human liver apolipoprotein AI and AII mRNA. Processing of primary translation products. Hoppe Seylers Z Physiol Chem. 1983;364:227-237.
6. Chau P, Fielding PE, Fielding CJ. Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. Biochemistry. 2007;46:8445-8450.
7. Zhu J, Gardner J, Pullinger CR, Kane JP, Thompson JF, Francone OL. Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1. J Lipid Res. 2009;50:1330-1339.
8. Gillard BK, Lin HY, Massey JB, Pownall HJ. Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta. 2009;1791:1125-1132.
9. Kiss RS, McManus DC, Franklin V, Tan WL, McKenzie A, Chimini G, Marcel YL. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and-independent pathways. J Biol Chem. 2003;278:10119-10127.
10. Ji A, Wroblewski JM, Cai L, de Beer MC, Webb NR, van der Westhuyzen DR. Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. J Lipid Res. 2012;53:446-455.
11. Maric J, Kiss RS, Franklin V, Marcel YL. Intracellular lipidation of newly synthesized apolipoprotein A-I in primary murine hepatocytes. J Biol Chem. 2005;280:39942-39949.
12. Nagata KO, Nakada C, Kasai RS, Kusumi A, Ueda K. ABCA1 dimer-monomer interconversion during HDL generation revealed by single-molecule imaging. Proc Natl Acad Sci USA. 2013;110:5034-5039.
13. Vedhachalam C, Liu L, Nickel M, Dhanasekaran P, Anantharamaiah GM, Lund-Katz S, Rothblat GH, Phillips MC. Infuence of ApoA-I structure on the ABCA1-mediated effux of cellular lipids. J Biol Chem. 2004;279:49931-49939.
14. Chroni A, Koukos G, Duka A, Zannis VI. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry. 2007;46:5697-5708.
15. Hassan HH, Denis M, Lee DY, Iatan I, Nyholt D, Ruel I, Krimbou L, Genest J. Identifcation of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. J Lipid Res. 2007;48:2428-2442.
16. Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol effux regulatory protein. J Biol Chem. 2001;276:23742-23747.
17. Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman MW. Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem. 2002;277:33178-33187.
18. Gillotte KL, Davidson WS, Lund-Katz S, Rothblat GH, Phillips MC. Removal of cellular cholesterol by pre-beta-HDL involves plasma membrane microsolubilization. J Lipid Res. 1998;39:1918-1928.
19. Smith JD, Le Goff W, Settle M, Brubaker G, Waelde C, Horwitz A, Oda MN. ABCA1 mediates concurrent cholesterol and phospholipid effux to apolipoprotein A-I. J Lipid Res. 2004;45:635-644.
20. Chung S, Sawyer JK, Gebre AK, Maeda N, Parks JS. Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation. 2011;124:1663-1672.
21. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052-1062.
22. Brunham LR, Kruit JK, Pape TD, Parks JS, Kuipers F, Hayden MR. Tissue-specifc induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ Res. 2006;99:672-674.
23. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661-663.
24. Alexander ET, Vedhachalam C, Sankaranarayanan S, de la Llera-Moya M, Rothblat GH, Rader DJ, Phillips MC. Infuence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 2011;31:320-327.
25. Patsch JR, Gotto AM Jr, Olivercrona T, Eisenberg S. Formation of high density lipoprotein2-like particles during lipolysis of very low density li-poproteins in vitro. Proc Natl Acad Sci USA. 1978;75:4519-4523.
26. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein defciency. Nat Genet. 1999;22:336-345.
27. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfe P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352-355.
28. Wang J, Burnett JR, Near S, Young K, Zinman B, Hanley AJ, Connelly PW, Harris SB, Hegele RA. Common and rare ABCA1 variants affecting plasma HDL cholesterol. Arterioscler Thromb Vasc Biol. 2000;20:1983-1989.
29. Forte T, Norum KR, Glomset JA, Nichols AV. Plasma lipoproteins in familial lecithin: cholesterol acyltransferase defciency: structure of low and high density lipoproteins as revealed by elctron microscopy. J Clin Invest. 1971;50:1141-1148.
30. Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G, Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT defciency states. J Lipid Res. 2007;48:592-599.
31. Liang HQ, Rye KA, Barter PJ. Remodelling of reconstituted high density lipoproteins by lecithin: cholesterol acyltransferase. J Lipid Res. 1996;37:1962-1970.
32. Forte TM, Bielicki JK, Goth-Goldstein R, Selmek J, McCall MR. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specifc HDL that differ in size, phospholipid composition, and reactivity with LCAT. J Lipid Res. 1995;36:148-157.
33. Hussain MM, Zannis VI. Intracellular modifcation of human apoli-poprotein AII (apoAII) and sites of apoAII mRNA synthesis: comparison of apoAII with apoCII and apoCIII isoproteins. Biochemistry. 1990;29:209-217.
34. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarina-Fojo S, Brewer HB Jr. Apolipoprotein specifcity for lipid effux by the human ABCAI transporter. Biochem Biophys Res Commun. 2001;280:818-823.
35. Bisgaier CL, Sachdev OP, Megna L, Glickman RM. Distribution of apoli-poprotein A-IV in human plasma. J Lipid Res. 1985;26:11-25.
36. Green PH, Glickman RM, Riley JW, Quinet E. Human apolipopro-tein A-IV. Intestinal origin and distribution in plasma. J Clin Invest. 1980;65:911-919.
37. Ezeh B, Haiman M, Alber HF, Kunz B, Paulweber B, Lingenhel A, Kraft HG, Weidinger F, Pachinger O, Dieplinger H, Kronenberg F. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res. 2003;44:1523-1529.
38. Karathanasis SK, Yunis I, Zannis VI. Structure, evolution, and tissue-specifc synthesis of human apolipoprotein AIV. Biochemistry. 1986; 25:3962-3970.
39. Duka A, Fotakis P, Georgiadou D, Kateifdes A, Tzavlaki K, von Eckardstein L, Stratikos E, Kardassis D, Zannis VI. ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. J Lipid Res. 2013;54:107-115.
40. Pearson K, Saito H, Woods SC, Lund-Katz S, Tso P, Phillips MC, Davidson WS. Structure of human apolipoprotein A-IV: a distinct domain architecture among exchangeable apolipoproteins with potential functional implications. Biochemistry. 2004;43:10719-10729.
41. Pearson K, Tubb MR, Tanaka M, Zhang XQ, Tso P, Weinberg RB, Davidson WS. Specifc sequences in the N and C termini of apolipopro-tein A-IV modulate its conformation and lipid association. J Biol Chem. 2005;280:38576-38582.
42. Mitchell CD, King WC, Applegate KR, Forte T, Glomset JA, Norum KR, Gjone E. Characterization of apolipoprotein E-rich high density lipopro-teins in familial lecithin:cholesterol acyltransferase defciency. J Lipid Res. 1980;21:625-634.
43. Krimbou L, Denis M, Haidar B, Carrier M, Marcil M, Genest J Jr. Molecular interactions between apoE and ABCA1: impact on apoE lipida-tion. J Lipid Res. 2004;45:839-848.
44. Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J. 2007;403:359-367.
45. Petropoulou PA, Gantz DL, Wang Y, Rensen PC, Kypreos KE. The ami-noterminal 1-185 domain of human apolipoprotein E suffces for the de novo biogenesis of apoE-containing HDL-like particles in apoA-I def-cient mice. Atherosclerosis. 2011;219:116-123.
46. Vezeridis AM, Chroni A, Zannis VI. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Ann Med. 2011;43:302-311.
47. Clee SM, Kastelein JJ, van Dam M, et al. Age and residual cholesterol ef-fux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest. 2000;106:1263-1270.
48. Hovingh GK, Van Wijland MJ, Brownlie A, Bisoendial RJ, Hayden MR, Kastelein JJ, Groen AK. The role of the ABCA1 transporter and cholesterol effux in familial hypoalphalipoproteinemia. J Lipid Res. 2003;44:1251-1255.
49. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest. 2004;114:1343-1353.
50. Candini C, Schimmel AW, Peter J, Bochem AE, Holleboom AG, Vergeer M, Dullaart RP, Dallinga-Thie GM, Hovingh GK, Khoo KL, Fasano T, Bocchi L, Calandra S, Kuivenhoven JA, Motazacker MM. Identifcation and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipopro-tein cholesterol. Atherosclerosis. 2010;213:492-498.
51. Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, Jukema JW, van Wijland M, van Dam M, Hudson TJ, Brooks-Wilson A, Genest J Jr, Kastelein JJ, Hayden MR. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modifed risk for coronary artery disease. Circulation. 2001;103:1198-1205.
52. Kakko S, Kelloniemi J, von Rohr P, Hoeschele I, Tamminen M, Brousseau ME, Kesäniemi YA, Savolainen MJ. ATP-binding cassette transporter A1 locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease. Atherosclerosis. 2003;166:285-290.
53. Venkateswaran A, Lafftte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P. Control of cellular cholesterol effux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA. 2000;97:12097-12102.
54. Chawla A, Boisvert WA, Lee CH, Lafftte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol effux and atherogenesis. Mol Cell. 2001;7:161-171.
55. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
56. Chen X, Guo Z, Okoro EU, Zhang H, Zhou L, Lin X, Rollins AT, Yang H. Up-regulation of ATP binding cassette transporter A1 expression by very low density lipoprotein receptor and apolipoprotein E receptor 2. J Biol Chem. 2012;287:3751-3759.
57. Yan D, Mäyränpää MI, Wong J, Perttilä J, Lehto M, Jauhiainen M, Kovanen PT, Ehnholm C, Brown AJ, Olkkonen VM. OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol effux from macrophages. J Biol Chem. 2008;283:332-340.
58. Bowden K, Ridgway ND. OSBP negatively regulates ABCA1 protein stability. J Biol Chem. 2008;283:18210-18217.
59. Iwamoto N, Abe-Dohmae S, Ayaori M, Tanaka N, Kusuhara M, Ohsuzu F, Yokoyama S. ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha. Doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis indepen dent of alpha1-adrenoceptor blockade. Circ Res. 2007;101:156-165.
60. Bowden KL, Bilbey NJ, Bilawchuk LM, Boadu E, Sidhu R, Ory DS, Du H, Chan T, Francis GA. Lysosomal acid lipase defciency impairs regulation of ABCA1 gene and formation of high density lipoproteins in choles-teryl ester storage disease. J Biol Chem. 2011;286:30624-30635.
61. Zhou X, Yin Z, Guo X, Hajjar DP, Han J. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol effux. J Biol Chem. 2010;285:6316-6326.
62. Lin S, Zhou C, Neufeld E, et al. BIG1, a brefeldin A-inhibited guanine nucleotide-exchange protein modulates ATP-binding cassette transporter A-1 traffcking and function. Arterioscler Thromb Vasc Biol. 2013;33:e31-e38.
63. Najaf-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Näär AM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328:1566-1569.
64. Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernández-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570-1573.
65. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, Marusawa H, Iwanaga Y, Hasegawa K, Yokode M, Kimura T, Kita T. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA. 2010;107:17321-17326.
66. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404-407.
67. Ramirez CM, Dávalos A, Goedeke L, Salerno AG, Warrier N, Cirera-Salinas D, Suárez Y, Fernández-Hernando C. MicroRNA-758 regulates cholesterol effux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol. 2011;31:2707-2714.
68. Kim J, Yoon H, Ramirez CM, Lee SM, Hoe HS, Fernandez-Hernando C. MiR-106b impairs cholesterol effux and increases abeta levels by repressing abca1 expression. Exp Neurol. 2012;235:476-483
69. Ramírez CM, Rotllan N, Vlassov AV, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res. 2013;112:1592-1601.
70. Sun D, Zhang J, Xie J, Wei W, Chen M, Zhao X. MiR-26 controls LXR-dependent cholesterol effux by targeting ABCA1 and ARL7. FEBS Lett. 2012;586:1472-1479.
71. Fu Y, Mukhamedova N, Ip S, D'Souza W, Henley KJ, DiTommaso T, Kesani R, Ditiatkovski M, Jones L, Lane RM, Jennings G, Smyth IM, Kile BT, Sviridov D. ABCA12 regulates ABCA1-dependent cholesterol effux from macrophages and the development of atherosclerosis. Cell Metab. 2013;18:225-238.
72. Wang N, Chen W, Linsel-Nitschke P, Martinez LO, Agerholm-Larsen B, Silver DL, Tall AR. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest. 2003;111:99-107.
73. Lu R, Arakawa R, Ito-Osumi C, Iwamoto N, Yokoyama S. ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intra-cellular degradation and increases HDL generation. Arterioscler Thromb Vasc Biol. 2008;28:1820-1824.
74. Singaraja RR, Kang MH, Vaid K, Sanders SS, Vilas GL, Arstikaitis P, Coutinho J, Drisdel RC, El-Husseini Ael D, Green WN, Berthiaume L, Hayden MR. Palmitoylation of ATP-binding cassette transporter A1 is essential for its traffcking and function. Circ Res. 2009;105:138-147.
75. Linder MD, Mäyränpää MI, Peränen J, Pietilä TE, Pietiäinen VM, Uronen RL, Olkkonen VM, Kovanen PT, Ikonen E. Rab8 regulates ABCA1 cell surface expression and facilitates cholesterol effux in primary human macrophages. Arterioscler Thromb Vasc Biol. 2009;29:883-888.
76. Haidar B, Kiss RS, Sarov-Blat L, Brunet R, Harder C, McPherson R, Marcel YL. Cathepsin D, a lysosomal protease, regulates ABCA1-mediated lipid effux. J Biol Chem. 2006;281:39971-39981.
77. Wang MD, Franklin V, Sundaram M, Kiss RS, Ho K, Gallant M, Marcel YL. Differential regulation of ATP binding cassette protein A1 expression and ApoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages. J Biol Chem. 2007;282:22525-22533.
78. Vaisman BL, Klein HG, Rouis M, Bérard AM, Kindt MR, Talley GD, Meyn SM, Hoyt RF Jr, Marcovina SM, Albers JJ. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoprotein-emia in transgenic mice. J Biol Chem. 1995;270:12269-12275.
79. Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipo-protein cholesterol metabolism. J Clin Invest. 1995;96:1440-1448.
80. Hoeg JM, Vaisman BL, Demosky SJ Jr, Meyn SM, Talley GD, Hoyt RF Jr, Feldman S, Bérard AM, Sakai N, Wood D, Brousseau ME, Marcovina S, Brewer HB Jr, Santamarina-Fojo S. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem. 1996;271:4396-4402.
81. Calabresi L, Pisciotta L, Costantin A, et al. The molecular basis of lecithin:cholesterol acyltransferase defciency syndromes: a comprehensive study of molecular and biochemical fndings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol. 2005;25:1972-1978.
82. Fielding CJ, Shore VG, Fielding PE. A protein cofactor of lecithin:cholesterol acyltransferase. Biochem Biophys Res Commun. 1972;46:1493-1498.
83. Scott BR, McManus DC, Franklin V, McKenzie AG, Neville T, Sparks DL, Marcel YL. The N-terminal globular domain and the frst class A am-phipathic helix of apolipoprotein A-I are important for lecithin:cholesterol acyltransferase activation and the maturation of high density lipoprotein in vivo. J Biol Chem. 2001;276:48716-48724.
84. Jonas A, Steinmetz A, Churgay L. The number of amphipathic alpha-helical segments of apolipoproteins A-I, E, and A-IV determines the size and functional properties of their reconstituted lipoprotein particles. J Biol Chem. 1993;268:1596-1602.
85. Zorich N, Jonas A, Pownall HJ. Activation of lecithin cholesterol acyl-transferase by human apolipoprotein E in discoidal complexes with lipids. J Biol Chem. 1985;260:8831-8837.
86. Rye KA, Bright R, Psaltis M, Barter PJ. Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E. J Lipid Res. 2006;47:1025-1036.
87. Hennessy LK, Kunitake ST, Jarvis M, Hamilton RL, Endeman G, Protter A, Kane JP. Isolation of subpopulations of high density lipoproteins: three particle species containing apoE and two species devoid of apoE that have affnity for heparin. J Lipid Res. 1997;38:1859-1868.
88. Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A, Mabuchi H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein defciency. J Lipid Res. 2004;45:448-455.
89. Böttcher A, Schlosser J, Kronenberg F, Dieplinger H, Knipping G, Lackner KJ, Schmitz G. Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions. J Lipid Res. 2000;41:905-915.
90. Mackie A, Caslake MJ, Packard CJ, Shepherd J. Concentration and distribution of human plasma apolipoprotein E. Clin Chim Acta. 1981;116:35-45.
91. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffnity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984;259:12201-12209.
92. Leren TP, Bakken KS, Daum U, Ose L, Berg K, Assmann G, von Eckardstein A. Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I. J Lipid Res. 1997;38:121-131.
93. Durbin DM, Jonas A. Lipid-free apolipoproteins A-I and A-II promote remodeling of reconstituted high density lipoproteins and alter their reactivity with lecithin:cholesterol acyltransferase. J Lipid Res. 1999;40:2293-2302.
94. Clay MA, Pyle DH, Rye KA, Barter PJ. Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin:cholesterol acyltransferase. J Biol Chem. 2000;275:9019-9025.
95. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. Distribution of ApoA-I-containing HDL subpopula-tions in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2670-2676.
96. Brousseau ME, Millar JS, Diffenderfer MR, Nartsupha C, Asztalos BF, Wolfe ML, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ. Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. J Lipid Res. 2009;50:1456-1462.
97. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
98. Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol ac-yltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem. 1996;271:19152-19158.
99. Rye KA, Hime NJ, Barter PJ. The infuence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J Biol Chem. 1996;271:4243-4250.
100. Subbaiah PV, Horvath P, Achar SB. Regulation of the activity and fatty acid specifcity of lecithin-cholesterol acyltransferase by sphingomyelin and its metabolites, ceramide and ceramide phosphate. Biochemistry. 2006;45:5029-5038.
101. Jonas A, Zorich NL, Kézdy KE, Trick WE. Reaction of discoidal complexes of apolipoprotein A-I and various phosphatidylcholines with lecithin cholesterol acyltransferase. Interfacial effects. J Biol Chem. 1987;262:3969-3974.
102. Jonas A, Kézdy KE, Wald JH. Defned apolipoprotein A-I conformations in reconstituted high density lipoprotein discs. J Biol Chem. 1989;264:4818-4824.
103. Jonas A, Wald JH, Toohill KL, Krul ES, Kézdy KE. Apolipoprotein A-I structure and lipid properties in homogeneous, reconstituted spherical and discoidal high density lipoproteins. J Biol Chem. 1990;265:22123-22129.
104. Fournier N, Myara I, Atger V, Moatti N. Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated high-density lipoproteins (HDL). Clin Chim Acta. 1995;234:47-61.
105. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia. 2007;50:643-653.
106. Cigliano L, Spagnuolo MS, Cuomo G, Valentini G, Niglio A, Abrescia P. Apolipoprotein A-I-dependent cholesterol esterifcation in patients with rheumatoid arthritis. Life Sci. 2005;77:108-120.
107. Spagnuolo MS, Cigliano L, D'Andrea LD, Pedone C, Abrescia P. Assignment of the binding site for haptoglobin on apolipoprotein A-I. J Biol Chem. 2005;280:1193-1198.
108. Bories PC, Subbaiah PV, Bagdade JD. Lecithin: cholesterol acyltransfer-ase activity in dialyzed and undialyzed chronic uremic patients. Nephron. 1982;32:22-27.
109. Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192-2196.
110. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
111. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 1997;17:1098-1105.
112. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981;665:408-419.
113. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 1988;27:25-29.
114. Huang Y, von Eckardstein A, Wu S, Maeda N, Assmann G. A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA. 1994;91:1834-1838.
115. Hayek T, Chajek-Shaul T, Walsh A, Agellon LB, Moulin P, Tall AR, Breslow JL. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J Clin Invest. 1992;90:505-510.
116. Freeman DJ, Griffn BA, Holmes AP, Lindsay GM, Gaffney D, Packard CJ, Shepherd J. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb. 1994;14:336-344.
117. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PW, Schaefer EJ. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipopro-tein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol. 2000;20:1323-1329.
118. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
119. Barter PJ, Hopkins GJ, Calvert GD. Transfers and exchanges of esterifed cholesterol between plasma lipoproteins. Biochem J. 1982;208:1-7.
120. Rye KA, Hime NJ, Barter PJ. The infuence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins. J Biol Chem. 1995;270:189-196.
121. Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow JL, Tall A. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest. 1994;94:2457-2467.
122. Murakami T, Michelagnoli S, Longhi R, Gianfranceschi G, Pazzucconi F, Calabresi L, Sirtori CR, Franceschini G. Triglycerides are major determinants of cholesterol esterifcation/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol. 1995;15:1819-1828.
123. Rye KA, Hime NJ, Barter PJ. Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J Biol Chem. 1997;272:3953-3960.
124. Rye KA, Barter PJ. The infuence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins. J Biol Chem. 1994;269:10298-10303.
125. Rye KA, Wee K, Curtiss LK, Bonnet DJ, Barter PJ. Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipopro-tein A-I formation. J Biol Chem. 2003;278:22530-22536.
126. Rye KA, Duong M, Psaltis MK, Curtiss LK, Bonnet DJ, Stocker R, Barter PJ. Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling. Biochemistry. 2002;41:12538-12545.
127. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipo-protein conversion. J Biol Chem. 1993;268:4032-4036.
128. Tu AY, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem. 1993;268:23098-23105.
129. Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR. Increased prebeta-high density lipoprotein, apolipopro-tein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest. 1996;98:2373-2380.
130. Ehnholm S, van Dijk KW, van 't Hof B, van der Zee A, Olkkonen VM, Jauhiainen M, Hofker M, Havekes L, Ehnholm C. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J Lipid Res. 1998;39:1248-1253.
131. Wolfbauer G, Albers JJ, Oram JF. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipo-protein apolipoproteins. Biochim Biophys Acta. 1999;1439:65-76.
132. Huuskonen J, Olkkonen VM, Ehnholm C, Metso J, Julkunen I, Jauhiainen M. Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion. Biochemistry. 2000;39:16092-16098.
133. Settasatian N, Duong M, Curtiss LK, Ehnholm C, Jauhiainen M, Huuskonen J, Rye KA. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem. 2001;276:26898-26905.
134. Vergeer M, Boekholdt SM, Sandhu MS, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation. 2010;122:470-477.
135. Settasatian N, Barter PJ, Rye KA. Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phos-pholipid transfer protein. J Lipid Res. 2008;49:115-126.
136. Pussinen PJ, Jauhiainen M, Ehnholm C. ApoA-II/apoA-I molar ratio in the HDL particle infuences phospholipid transfer protein-mediated HDL interconversion. J Lipid Res. 1997;38:12-21.
137. Rye KA, Jauhiainen M, Barter PJ, Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J Lipid Res. 1998;39:613-622.
138. Huuskonen J, Olkkonen VM, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. Acyl chain and headgroup specifcity of human plasma phos-pholipid transfer protein. Biochim Biophys Acta. 1996;1303:207-214.
139. Clay MA, Newnham HH, Barter PJ. Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler Thromb. 1991;11:415-422.
140. Barrans A, Collet X, Barbaras R, Jaspard B, Manent J, Vieu C, Chap H, Perret B. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem. 1994;269:11572- 11577.
141. Guerra R, Wang J, Grundy SM, Cohen JC. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci USA. 1997;94:4532-4537.
142. Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, Brunzell JD. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol. 2002;22:667-673.
143. Fan J, Wang J, Bensadoun A, Lauer SJ, Dang Q, Mahley RW, Taylor JM. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci USA. 1994;91:8724-8728.
144. Busch SJ, Barnhart RL, Martin GA, Fitzgerald MC, Yates MT, Mao SJ, Thomas CE, Jackson RL. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem. 1994;269:16376-16382.
145. Hime NJ, Barter PJ, Rye KA. The infuence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospho-lipid and triacylglycerol. J Biol Chem. 1998;273:27191-27198.
146. Hime NJ, Barter PJ, Rye KA. Evidence that apolipoprotein A-I facilitates hepatic lipase-mediated phospholipid hydrolysis in reconstituted HDL containing apolipoprotein A-II. Biochemistry. 2001;40:5496-5505.
147. Hime NJ, Drew KJ, Hahn C, Barter PJ, Rye KA. Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner. Biochemistry. 2004;43:12306-12314.
148. Thuren T, Weisgraber KH, Sisson P, Waite M. Role of apolipoprotein E in hepatic lipase catalyzed hydrolysis of phospholipid in high-density lipoproteins. Biochemistry. 1992;31:2332-2338.
149. Duong M, Psaltis M, Rader DJ, Marchadier D, Barter PJ, Rye KA. Evidence that hepatic lipase and endothelial lipase have different substrate specifcities for high-density lipoprotein phospholipids. Biochemistry. 2003;42:13778-13785.
150. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M, Rader DJ. A novel endothelial-derived li-pase that modulates HDL metabolism. Nat Genet. 1999;21:424-428.
151. Hirata K, Dichek HL, Cioff JA, Choi SY, Leeper NJ, Quintana L, Kronmal GS, Cooper AD, Quertermous T. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem. 1999;274:14170-14175.
152. Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA. Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res. 2005;46:896-903.
153. Maugeais C, Tietge UJ, Broedl UC, Marchadier D, Cain W, McCoy MG, Lund-Katz S, Glick JM, Rader DJ. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation. 2003;108:2121-2126.
154. Ishida T, Choi S, Kundu RK, Hirata K, Rubin EM, Cooper AD, Quertermous T. Endothelial lipase is a major determinant of HDL level. J Clin Invest. 2003;111:347-355.
155. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest. 2003;111:357-362.
156. Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipo-protein concentration, structure, and metabolism. Proc Natl Acad Sci USA. 2003;100:2748-2753
157. deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ. Identifcation of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation. 2002;106:1321-1326.
158. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest. 2009;119:1042-1050.
159. Singaraja RR, Sivapalaratnam S, Hovingh K, et al. The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. Circ Cardiovasc Genet. 2013;6:54-62.
160. Caiazza D, Jahangiri A, Rader DJ, Marchadier D, Rye KA. Apolipoproteins regulate the kinetics of endothelial lipase-mediated hydrolysis of phospholipids in reconstituted high-density lipoproteins. Biochemistry. 2004;43:11898-11905.
161. Broedl UC, Jin W, Fuki IV, Millar JS, Rader DJ. Endothelial lipase is less effective at infuencing HDL metabolism in vivo in mice expressing apoA-II. J Lipid Res. 2006;47:2191-2197.
162. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, Rader DJ. Overexpression of secretory phospholipase A(2) causes rapid catab-olism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem. 2000;275:10077-10084.
163. de Beer FC, de Beer MC, van der Westhuyzen DR, Castellani LW, Lusis AJ, Swanson ME, Grass DS. Secretory non-pancreatic phospholipase A2: infuence on lipoprotein metabolism. J Lipid Res. 1997;38:2232-2239.
164. Burton CA, Patel S, Mundt S, Hassing H, Zhang D, Hermanowski-Vosatka A, Wright SD, Chao YS, Detmers PA, Sparrow CP. Defciency in sPLA(2) does not affect HDL levels or atherosclerosis in mice. Biochem Biophys Res Commun. 2002;294:88-94.
165. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identifcation of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
166. Brundert M, Ewert A, Heeren J, Behrendt B, Ramakrishnan R, Greten H, Merkel M, Rinninger F. Scavenger receptor class B type I mediates the selective uptake of high-density lipoprotein-associated cholesteryl ester by the liver in mice. Arterioscler Thromb Vasc Biol. 2005;25:143-148.
167. Lambert G, Chase MB, Dugi K, Bensadoun A, Brewer HB Jr, Santamarina-Fojo S. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J Lipid Res. 1999;40:1294-1303.
168. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414-417.
169. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipopro-tein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA. 1997;94:12610-12615.
170. Webb NR, Cai L, Ziemba KS, Yu J, Kindy MS, van der Westhuyzen DR, de Beer FC. The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res. 2002;43:1890-1898.
171. Webb NR, de Beer MC, Asztalos BF, Whitaker N, van der Westhuyzen DR, de Beer FC. Remodeling of HDL remnants generated by scavenger receptor class B type I. J Lipid Res. 2004;45:1666-1673.
172. Liang HQ, Rye KA, Barter PJ. Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools. Biochim Biophys Acta. 1995;1257:31-37.
173. Gauthier A, Lau P, Zha X, Milne R, McPherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipo-protein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol. 2005;25:2177-2184.
174. Xu S, Laccotripe M, Huang X, Rigotti A, Zannis VI, Krieger M. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res. 1997;38:1289-1298.
175. Pilon A, Briand O, Lestavel S, Copin C, Majd Z, Fruchart JC, Castro G, Clavey V. Apolipoprotein AII enrichment of HDL enhances their affnity for class B type I scavenger receptor but inhibits specifc cholesteryl ester uptake. Arterioscler Thromb Vasc Biol. 2000;20:1074-1081.
176. Arai T, Rinninger F, Varban L, Fairchild-Huntress V, Liang CP, Chen W, Seo T, Deckelbaum R, Huszar D, Tall AR. Decreased selective uptake of high density lipoprotein cholesteryl esters in apolipoprotein E knock-out mice. Proc Natl Acad Sci USA. 1999;96:12050-12055.
177. Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S, Christensen EI, Aminoff M, de la Chapelle A, Krahe R, Verroust PJ, Moestrup SK. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affnity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med. 1999;5:656-661.
178. Hammad SM, Stefansson S, Twal WO, Drake CJ, Fleming P, Remaley A, Brewer HB Jr, Argraves WS. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipo-protein holoparticle endocytosis. Proc Natl Acad Sci USA. 1999; 96:10158-10163.
179. Hammad SM, Barth JL, Knaak C, Argraves WS. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem. 2000;275:12003-12008.
180. Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, Burns DK, Herz J. Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci USA. 1996;93:8460-8464.
181. Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA, Serone AP, Barrett PH. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab. 2006;91:973-979.
182. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, Nakamura H. Delayed catabo-lism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein defciency. J Clin Invest. 1993; 92:1650-1658.
183. Singaraja RR, Stahmer B, Brundert M, Merkel M, Heeren J, Bissada N, Kang M, Timmins JM, Ramakrishnan R, Parks JS, Hayden MR, Rinninger F. Hepatic ATP-binding cassette transporter A1 is a key molecule in high-density lipoprotein cholesteryl ester metabolism in mice. Arterioscler Thromb Vasc Biol. 2006;26:1821-1827.
184. Gylling H, Miettinen TA. Non-cholesterol sterols, absorption and synthesis of cholesterol and apolipoprotein A-I kinetics in a Finnish lecithin-cholesterol acyltransferase defcient family. Atherosclerosis. 1992;95:25-33.
185. Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, Clerc M, Dumon MF, Fairwell T, Zech L. Markedly accelerated catabo-lism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase defciency and fsh-eye disease. J Clin Invest. 1994;93:321-330.